An observational study in T-Cell Leukemia/Lymphoma, Adult, sponsored by Istituto Oncologico Veneto IRCCS. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Istituto Oncologico Veneto IRCCS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy — 6 open to participants now, 9 under way, 1 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Italy.
Among the 27 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy, this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 27th registered.
420 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 76 are open to participants now.
Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →6 of the 27 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy are open now. Recruiting first, the newest first:
Princess Maxima Center for Pediatric Oncology · Sites in Italy, Austria, Belgium and 11 more countries
Ages 1–21
Princess Maxima Center for Pediatric Oncology · Sites in Italy, Austria, Belgium and 11 more countries
Ages 1–21
Bambino Gesù Hospital and Research Institute · Sites in Italy
Ages 6 mo–25 yrs
Princess Maxima Center for Pediatric Oncology · Sites in Italy, Austria, Belgium and 12 more countries
Ages 1–21
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 60 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 24 (40%) set no upper age limit and 31 (52%) stop at 75 or younger; 36 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 16 · Phase 3 2
First in 1994; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 82 across 30 observational studies indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 34 across the 22 interventional studies, 110 across the 4 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 27 have an industry lead sponsor. The 10 most frequent:
Istituto Oncologico Veneto IRCCS is the lead sponsor of 47 studies on the registry; 13 are open to participants now.
Istituto Oncologico Veneto IRCCS has 1 study filed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06600568Istituto Oncologico Veneto IRCCSNovel Therapeutic Approach for Human T-cell Malignancies | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined.
The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.
Up to a maximum of 120 patients (both retrospective and prospective) are expected to be enrolled during the study period. Specifically, a maximum of 40 patients will be enrolled for each of the following diseases: T-cell lymphoblastic leukemias (T-ALL); T-cell non-Hodgkin lymphomas (T-NHL); NK-cell neoplasms. For retrospective peripheral blood samples, bone marrow aspirates, and lymph node biopsies, which are available at the centers involved in the study, patients will be contacted again to ask for consent regarding this project.
No additional clinical procedures are specifically required by participation in the present study. In fact, samples will be obtained from the material left over from samples taken for clinical procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Novel strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
Primary outcome
Response of leukemic cells to treatments that remodulate redox state and apoptosis from a molecular point of view, ex vivo,through the development of a multidimensional approach aimed at reducing the chemoresistance of T neoplasms
Time frame: Through study completion, an average of 2 years
Secondary outcome
Development of drug combinations that can selectively eliminate T-cell leukemia/lymphoma cells
Time frame: Through study completion, an average of 2 years
Secondary outcome
Analysis of DNA, RNA, protein, and circulating markers of alterations present at baseline in patient samples; profiles obtained will be correlated with response to drug treatments in order to identify biomarkers predictive of response to treatment.
Time frame: Through study completion, an average of 2 years
Secondary outcome
Analysis of the efficacy of new drug combinations in vivo through the generation of PDX-based experimental mouse models derived from patients with T-cell malignancies.
Time frame: Through study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma →
Istituto Oncologico Veneto IRCCS